Evaluating the potential role of oral activated charcoal as an adjunct treatment for severe bacterial infections and severe malaria - a preliminary safety study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN64793756

Enrollment

Registered

2006-08-08

Start date

2006-05-29

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asymptomatic parasitaemia for Plasmodium falciparum Infections and Infestations Asymptomatic parasitaemia for Plasmodium falciparum

Interventions

Co-administration of oral activated charcoal and intravenous (i.v.) artesunate to study participants randomised into three groups as follows: Group one (control): i.v. artesunate without adjuvant trea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy African adults aged 15-45 years with asymptomatic parasitaemia confirmed on a thick blood film.

Exclusion criteria

Exclusion criteria: 1. Haemoglobin less than 11 g/dl 2. Detectable levels of chloroquine in the urine 3. Mixed infections 4. Concurrent participation in another study 5. Pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
Impact of oral activated charcoal on the pharmacokinetics of parenteral artesunate.	—

Secondary

Measure	Time frame
Reduced parasite clearance of i.v. artesunate	—

Countries

Gambia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026